Molecular dynamics approach to probe the allosteric inhibition of PTP1B by chlorogenic and cichoric acid

Related Experiment Video

Updated: May 20, 2026

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
13:35

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

Sarath Kumar Baskaran1, Nabajyoti Goswami, Sudhagar Selvaraj

  • 1Centre for Biotechnology, Anna University, Chennai, India.

Journal of Chemical Information and Modeling
|July 4, 2012
PubMed

Insights

Chlorogenic acid (CGA) and cichoric acid (CHA) show potential for treating diabetes and obesity by inhibiting Protein tyrosine phosphatase 1B (PTP1B). These compounds bind to PTP1B's allosteric site, offering a novel therapeutic strategy.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Computational Biology

Background:

  • Protein tyrosine phosphatase 1B (PTP1B) is a key regulator of insulin and leptin signaling, making it a therapeutic target for diabetes and obesity.
  • The discovery of an allosteric site in PTP1B offers a new avenue for drug development.
  • Caffeoyl derivatives like chlorogenic acid (CGA) and cichoric acid (CHA) are being explored for their therapeutic potential.

Purpose of the Study:

  • To investigate the molecular interactions between PTP1B's allosteric site and CGA/CHA.
  • To elucidate the mechanism of allosteric inhibition by CGA and CHA on PTP1B.

Main Methods:

  • Computational strategies including molecular docking and molecular dynamics (MD) simulations.
  • MD simulations were conducted for 10 ns to analyze the stability and interactions of protein-ligand complexes.

Main Results:

  • Both CGA and CHA demonstrated stable binding at the allosteric site of PTP1B.
  • CGA and CHA constrained the WPD loop flexibility in the open (inactive) state of PTP1B, revealing a mechanism for allosteric inhibition.
  • The binding of CGA and CHA at the allosteric site was not hindered by the α-7 helix.

Conclusions:

  • CGA and CHA exhibit an inhibitory effect on PTP1B through potent binding at its allosteric site.
  • These findings support the development of CGA and CHA as potential therapeutic agents for diabetes and obesity by targeting PTP1B.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

Related Concept Videos

Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...